Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, Yohe ME, Sindiri S, Wei J, Wen X, Rudzinski ER, Barkauskas DA, Lo T, Hall D, Linardic CM, Hughes D, Jamal S, Jenney M, Chisholm J, Brown R, Jones K, Hicks B, Angelini P, George S, Chesler L, Hubank M, Kelsey A, Gatz SA, Skapek SX, Hawkins DS, Shipley JM, Khan J. Shern JF, et al. Among authors: chisholm j. J Clin Oncol. 2021 Sep 10;39(26):2859-2871. doi: 10.1200/JCO.20.03060. Epub 2021 Jun 24. J Clin Oncol. 2021. PMID: 34166060 Free PMC article.
Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma.
Chisholm JC, Machin D, McDowell H, McHugh K, Ellershaw C, Jenney M, Foot AB; Children's Cancer and Leukaemia Group (CCLG; formerly United Kingdom Children's Cancer Study Group). Chisholm JC, et al. Eur J Cancer. 2007 Nov;43(17):2537-44. doi: 10.1016/j.ejca.2007.08.024. Epub 2007 Oct 24. Eur J Cancer. 2007. PMID: 17962012 Clinical Trial.
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J. Missiaglia E, et al. Among authors: chisholm j. J Clin Oncol. 2012 May 10;30(14):1670-7. doi: 10.1200/JCO.2011.38.5591. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454413
Inconvenience of convenience cohorts--letter.
Williamson D, Missiaglia E, Chisholm J, Shipley J. Williamson D, et al. Among authors: chisholm j. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1388. doi: 10.1158/1055-9965.EPI-12-0724. Epub 2012 Jun 26. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22736787 Free PMC article. No abstract available.
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.
Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Morgenstern DA, et al. Among authors: chisholm jc. J Pediatr Hematol Oncol. 2014 Apr;36(3):218-23. doi: 10.1097/MPH.0000000000000003. J Pediatr Hematol Oncol. 2014. PMID: 24322496
Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols.
Ferrari A, Trama A, De Paoli A, Bergeron C, Merks JHM, Jenney M, Orbach D, Chisholm JC, Gallego S, Glosli H, De Salvo GL, Botta L, Gatta G, Bisogno G; RARECAREnet Working Group. Ferrari A, et al. Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26348. Epub 2016 Nov 24. Pediatr Blood Cancer. 2017. PMID: 27882658
450 results